TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04120688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D generated tooth replica
Description: 3D generated tooth replicas are compared to conventional procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D generated tooth replica
Description: 3D generated tooth replicas are compared to conventional procedure
Study: NCT01748799

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
Study: NCT03669523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab-nivolumab combination
Description: * Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks
Study: NCT01032629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule taken orally (by mouth) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily
Study: NCT01617538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 40mg per day,duration for 24 weeks
Study: NCT03371355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Matched with ISIS 703802)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 703802 40 mg
Description: ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 703802 80 mg
Description: ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 703802 20 mg
Description: ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
Study: NCT02236689

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non operative
Description: no surgical intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic tennis elbow release
Description: Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
Study: NCT01511731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine Tablets 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepcid
Description: 40mg tablets
Study: NCT05011084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready Cryotherapy with Compression Group
Description: Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Cryotherapy Group
Description: Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
Study: NCT00476099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
Description: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
Description: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
Description: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 µg plus formoterol 6 µg DPI
Description: two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200 µg plus formoterol 6 µg DPI
Description: two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200 µg plus formoterol 6 µg DPI
Description: two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol 12 µg DPI
Description: one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 µg DPI
Description: one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 µg DPI
Description: one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
Study: NCT04920240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cleaning and disinfection mode for surfaces with high frequency contact
Description: According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine procedure
Description: clean the high frequency contact surface like other surfaces
Study: NCT02829879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% arginine/1450ppm sodium monofluorophosphate dentifrice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% potassium nitrate/2500ppm sodium fluoride dentifrice
Study: NCT03841552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Feedback
Description: An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
Study: NCT00799526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Ex Vivo Conjunctival for Symblepharon Transplantation
Description: Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Conjunctival for Symblepharon Transplantation
Description: The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
Study: NCT04329026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glasses
Description: The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
Study: NCT02235649

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognition therapy ( Psychological Therapy)
Study: NCT02210156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omniplus Supreme
Description: Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
Study: NCT03501862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (psychosis)
Description: A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation (psychosis)
Description: A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
Study: NCT03462251

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ribociclib and aromatase inhibitor or fulvestrant
Description: Combination of ribociclib and aromatase inhibitor or fulvestrant

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
Description: Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
Study: NCT03403400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRWP Group
Description: The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VRW Group
Description: The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
Study: NCT03429868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: integrated PET/MRI
Description: The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan.
Study: NCT02683369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blood Builder®/Iron Response®
Description: The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root
Study: NCT01124825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IGEL
Description: iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King airway
Description: KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
Study: NCT02604004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epivir ® tablet 150-mg single dose (drug reference)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epivir ® tablet 150-mg single dose (drug reference)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine 150-mg tablet single dose (drug test)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 150-mg tablet single dose (drug test)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study: NCT02747485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myocardial biopsy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood samples
Description: extract DNA to look for genomic mutations associated with the disease.
Study: NCT00977470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 1000 mg taken orally once daily after erlotinib
Study: NCT04209231

Intervention type: OTHER
Intervention: 1.25(OH)2D3

Intervention type: OTHER
Intervention: 1.25(OH)2D3

Intervention type: OTHER
Intervention: 1.25(OH)2D3

Intervention type: OTHER
Intervention: 25(OH)D

Intervention type: OTHER
Intervention: 25(OH)D

Intervention type: OTHER
Intervention: 25(OH)D
Study: NCT02965378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor AZD4547
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor AZD4547
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00895063

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Vocal Exercise
Description: This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Exercise
Description: This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
Study: NCT00787436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
Study: NCT03276299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: six minute walking test
Description: six minute walking test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Description: six minute walking test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: six minute walking test
Description: six minute walking test with encouragement
Study: NCT01936155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-built, two-channel stimulator
Description: Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
Study: NCT02625584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Together - Pausing for Reading
Study: NCT01429571

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02813018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.2 ml/kg of 0.2% ropivacaine
Description: In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 0.2mg/kg of Normal Saline
Description: In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.